Abstract 180P
Background
Circadian rhythms (CRs) are crucial biological processes that influence various physiological functions in humans. Previous studies from our team have shown that chronic circadian disruption, specifically chronic jetlag (CJL), increases tumor burden in a mouse melanoma model. The tumor immune microenvironment plays a complex regulatory role in tumorigenesis. However, the specific immune cell functions regulated by circadian disruption to promote tumor progression remain largely undefined. This study aims to demonstrate the critical role of NK cells in the innate immune system during circadian disruption across various mouse models.
Methods
We utilized three distinct mouse models representing varying immune states: C57BL/6 mice, NOD-SCID mice (lacking T/B cells), and B-NDG mice (lacking T/B/NK cells), melanomas were inoculated subcutaneously. Light was manipulated to modulate the circadian clock. Mice were maintained under normal light-dark environment (LD) or CJL environment (6-hour advance of the LD12:12 cycle every 2 days). We use RNA-seq, flow cytometry and quantitative immunofluorescence to analysis tumor immune microenvironment.
Results
Our findings indicate that tumor growth rates significantly increased under CJL in C57 and NOD-SCID mice compared to normal light-dark schedules. In contrast, the tumor growth rate difference between the two rhythm patterns disappeared in NK-cell-deficient B-NDG mice. Flow cytometry analysis revealed that in C57 mice, CJL led to an increase in CD8+ T cells and a decrease in NK cells in tumors, with similar trends observed in the spleen. Additionally, RNA-seq data indicated that CJL inhibits pathways related to both innate and adaptive immunity in tumors, significantly downregulating NK cell function pathways.
Conclusions
These data demonstrate that chronic circadian disruption promotes tumor progression by altering the tumor immune microenvironment, with changes in NK cell quantity and function playing a pivotal role in CJL's effects on tumor growth.
Legal entity responsible for the study
West China Hospital, Sichuan University.
Funding
Sichuan Science and Technology Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
53P - Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Presenter: Saket Srivastava
Session: Poster Display session
Resources:
Abstract
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract